Merck reports positive data from STRIDE─10 phase 3 trial of V116, an investigational, 21─valent pneumococcal conjugate ...
Merck, known as MSD outside of the United States and Canada, announced results from STRIDE-10, a phase 3 trial evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 34th European Society of Clinical …